Cerus announces Health Canada approval of INTERCEPT Blood System for platelets
Cerus announced that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets. The INTERCEPT Blood System for platelets is intended for the ex vivo treatment and storage of platelet components. The system is used to inactivate a broad range of pathogens. April 25, 2018